Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 4 2Phase 3 2Phase 2/3 2Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Lymphoma, Non-Hodgkin 3Recurrence 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Hodgkin Disease 2Various Advanced Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms by Site 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Liver Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Gastroesophageal Cancer 1Fallopian Tube Neoplasms 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Advanced Cancer 1

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 32Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 16Biopsy 11trametinib 10fludarabine phosphate 10dabrafenib 10spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × relatlimab × Clear all
NCT07281924 2026-05-29

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

University of Wisconsin, Madison

Phase 1/2 Recruiting
15 enrolled
Dermatologic

Melanoma

NCT06683755 2024-11-12

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡